Eplontersen

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Drug Information

Target Indication

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Clinical Trial

Last updated: 7/7/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

AZNCF

ASTRAZENECA PLC

Related Pipeline

Anxiety Disorders

Healthy Japanese Children Age 2 Years Through 6 Years

Generalized Anxiety Disorder

Metastatic Castration-resistant Prostate Cancer

Triple Negative Breast Neoplasms

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts